{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:01:33Z","timestamp":1794852093704,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014107","name":"Stichting TSC Fonds","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014107","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Molecular Autism"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberous sclerosis complex (TSC) is an autosomal dominant disease that affects multiple organs including the brain. TSC is strongly associated with broad neurodevelopmental disorders, including autism spectrum disorder symptomatology. Preclinical TSC studies have indicated altered neuronal chloride homeostasis affecting the polarity of \u03b3-aminobutyric acid (GABA) ergic transmission as a potential treatment target. Bumetanide, a selective NKCC1 chloride importer antagonist, may attenuate depolarizing GABA action, and in that way reduce disease burden. In this open-label pilot study, we tested the effect of bumetanide on a variety of neurophysiological, cognitive, and behavioral measures in children with TSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were treated with bumetanide (2dd 0.5\u20131.0\u2009mg) for 13\u2009weeks in an open-label trial. The Aberrant Behavior Checklist-Irritability (ABC-I) subscale was chosen as the primary endpoint. Secondary endpoints included other behavioral questionnaires in addition to event-related potentials (ERP) and neuropsychological tests if tolerated. Additionally, the treatment effect on seizure frequency and quality of life was assessed. Endpoint data were collected at baseline, after 91\u2009days of treatment and after a 28-day wash-out period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifteen patients (8\u201321-years old) with TSC were included of which 13 patients completed the study. Treatment was well-tolerated with only expected adverse events due to the diuretic effects of bumetanide. Irritable behavior (ABC-I) showed significant improvement after treatment in 11 out of 13 patients (\n                      <jats:italic>t<\/jats:italic>\n                      (12) = 4.41,\n                      <jats:italic>p<\/jats:italic>\n                      = .001,\n                      <jats:italic>d<\/jats:italic>\n                      = .773). A favorable effect was also found for social behavior (Social Responsiveness Scale) (\n                      <jats:italic>t<\/jats:italic>\n                      (11) = 4.01,\n                      <jats:italic>p<\/jats:italic>\n                      = .002,\n                      <jats:italic>d<\/jats:italic>\n                      = .549) and hyperactive behavior (ABC-hyperactivity subscale)\n                      <jats:italic>(t<\/jats:italic>\n                      (12) = 3.65,\n                      <jats:italic>p<\/jats:italic>\n                      = .003,\n                      <jats:italic>d<\/jats:italic>\n                      = .686). Moreover, patients rated their own health-related quality of life higher after treatment. At baseline, TSC patients showed several atypical ERPs versus typically developing peers of which prepulse inhibition was significantly decreased in the TSC group. Neuropsychological measurements showed no change and bumetanide had no effect on seizure frequency.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>The sample size and open-label design of this pilot study warrant caution when interpreting outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC. More elaborate trials are needed to determine the application and effect size of bumetanide for the TSC population.<\/jats:p>\n                    <jats:p>Trial registration<\/jats:p>\n                    <jats:p>\n                      EU Clinical Trial Register, EudraCT 2016-002408-13 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002408-13\/NL\">www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002408-13\/NL<\/jats:ext-link>\n                      ). Registered 25 July 2016.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13229-020-00335-4","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T06:02:57Z","timestamp":1588831377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study"],"prefix":"10.1186","volume":"11","author":[{"given":"Dorinde M.","family":"van Andel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Sprengers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Oranje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floortje E.","family":"Scheepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor E.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilgo","family":"Bruining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"issue":"9639","key":"335_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657\u201368.","journal-title":"Lancet"},{"issue":"7","key":"335_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","volume":"14","author":"P Curatolo","year":"2015","unstructured":"Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733\u201345.","journal-title":"Lancet Neurol"},{"issue":"7","key":"335_CR3","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","volume":"51","author":"CJ Chu-Shore","year":"2010","unstructured":"Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236\u201341.","journal-title":"Epilepsia"},{"issue":"4","key":"335_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H, Group ITSCC. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255\u201365.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"335_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","volume":"52","author":"PJ de Vries","year":"2015","unstructured":"de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol. 2015;52(1):25\u201335.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"335_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","volume":"12","author":"JC Kingswood","year":"2017","unstructured":"Kingswood JC, d\u2019Aug\u00e8res GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA)\u2014baseline data on 2093 patients. Orphanet Journal of Rare Diseases. 2017;12(1):2.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"3","key":"335_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.nurt.2010.05.001","volume":"7","author":"PJ de Vries","year":"2010","unstructured":"de Vries PJ. Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics. 2010;7(3):275\u201382.","journal-title":"Neurotherapeutics"},{"key":"335_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s13063-016-1446-6","volume":"17","author":"E Randell","year":"2016","unstructured":"Randell E, McNamara R, Davies DM, Owen-Jones E, Kirby N, Angel L, et al. The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial. Trials. 2016;17:398.","journal-title":"Trials"},{"issue":"12","key":"335_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/acn3.494","volume":"4","author":"DA Krueger","year":"2017","unstructured":"Krueger DA, Sadhwani A, Byars AW, de Vries PJ, Franz DN, Whittemore VH, et al. Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. Ann Clin Transl Neurol. 2017;4(12):877\u201387.","journal-title":"Ann Clin Transl Neurol"},{"key":"335_CR10","doi-asserted-by":"crossref","unstructured":"Overwater IE, Rietman AB, Mous SE, Bindels-de Heus K, Rizopoulos D, Ten Hoopen LW, et al. A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex. Neurology. 2019.","DOI":"10.1212\/WNL.0000000000007749"},{"issue":"4","key":"335_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/ana.22696","volume":"71","author":"DM Talos","year":"2012","unstructured":"Talos DM, Sun H, Kosaras B, Joseph A, Folkerth RD, Poduri A, et al. Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. Ann Neurol. 2012;71(4):539\u201351.","journal-title":"Ann Neurol"},{"issue":"9","key":"335_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.tins.2017.07.001","volume":"40","author":"Y Ben-Ari","year":"2017","unstructured":"Ben-Ari Y. NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders. Trends Neurosci. 2017;40(9):536\u201354.","journal-title":"Trends Neurosci"},{"key":"335_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nbd.2016.07.014","volume":"95","author":"G Ruffolo","year":"2016","unstructured":"Ruffolo G, Iyer A, Cifelli P, Roseti C, Muhlebner A, van Scheppingen J, et al. Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions. Neurobiol Dis. 2016;95:93\u2013101.","journal-title":"Neurobiol Dis"},{"key":"335_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neuropharm.2012.05.045","volume":"69","author":"W Loscher","year":"2013","unstructured":"Loscher W, Puskarjov M, Kaila K. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology. 2013;69:62\u201374.","journal-title":"Neuropharmacology."},{"key":"335_CR15","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1038\/ncomms5563","volume":"5","author":"N Lozovaya","year":"2014","unstructured":"Lozovaya N, Gataullina S, Tsintsadze T, Tsintsadze V, Pallesi-Pocachard E, Minlebaev M, et al. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model. Nature Commun. 2014;5:4563.","journal-title":"Nature Commun"},{"key":"335_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fnins.2019.00310","volume":"13","author":"SC Kharod","year":"2019","unstructured":"Kharod SC, Kang SK, Kadam SD. Off-Label use of bumetanide for brain disorders: an overview. Front Neurosci. 2019;13:310.","journal-title":"Front Neurosci"},{"key":"335_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neubiorev.2018.05.001","volume":"90","author":"JT Schulte","year":"2018","unstructured":"Schulte JT, Wierenga CJ, Bruining H. Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions. Neurosci Biobehav Rev. 2018;90:260\u201371.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"335_CR18","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/j.1528-1167.2012.03654.x","volume":"54","author":"S Eftekhari","year":"2013","unstructured":"Eftekhari S, Mehvari Habibabadi J, Najafi Ziarani M, Hashemi Fesharaki SS, Gharakhani M, Mostafavi H, et al. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013;54(1):e9\u201312.","journal-title":"Epilepsia"},{"issue":"5","key":"335_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/0883073809333526","volume":"24","author":"KT Kahle","year":"2009","unstructured":"Kahle KT, Barnett SM, Sassower KC, Staley KJ. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. J Child Neurol. 2009;24(5):572\u20136.","journal-title":"J Child Neurol"},{"issue":"4","key":"335_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA. International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"335_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.101","volume":"7","author":"E Lemonnier","year":"2017","unstructured":"Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry. 2017;7(5):e1124.","journal-title":"Transl Psychiatry"},{"issue":"5","key":"335_CR22","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Mental Deficiency. 1985;89(5):485\u201391.","journal-title":"Am J Mental Deficiency"},{"issue":"4","key":"335_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/A:1025014929212","volume":"33","author":"JN Constantino","year":"2003","unstructured":"Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord. 2003;33(4):427\u201333.","journal-title":"J Autism Dev Disord"},{"key":"335_CR24","volume-title":"Sensory profile: User's manual: Psychological Corporation San Antonio, TX","author":"W Dunn","year":"1999","unstructured":"Dunn W. Sensory profile: User's manual: Psychological Corporation San Antonio, TX; 1999."},{"key":"335_CR25","volume-title":"Sensory profile-school companion manual","author":"W Dunn","year":"2006","unstructured":"Dunn W. Sensory profile-school companion manual. San Antonio, TX: Psychological Corporation; 2006."},{"issue":"5","key":"335_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10803-006-0213-z","volume":"37","author":"KS Lam","year":"2007","unstructured":"Lam KS, Aman MG. The Repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37(5):855\u201366.","journal-title":"J Autism Dev Disord"},{"key":"335_CR27","volume-title":"BRIEF-2: Behavior rating inventory of executive function: professional manual: psychological assessment resources","author":"GA Gioia","year":"2015","unstructured":"Gioia GA, Isquith PK, Guy SC, Kenworthy L. BRIEF-2: Behavior rating inventory of executive function: professional manual: psychological assessment resources; 2015."},{"issue":"3","key":"335_CR28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1017\/S0033291798006667","volume":"28","author":"Group W","year":"1998","unstructured":"Group W. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychological medicine. 1998;28(3):551\u20138.","journal-title":"Psychological medicine."},{"issue":"10","key":"335_CR29","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5\u2009L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"6","key":"335_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s11136-010-9648-y","volume":"19","author":"N Wille","year":"2010","unstructured":"Wille N, Badia X, Bonsel G, Burstr\u00f6m K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875\u201386.","journal-title":"Qual Life Res"},{"issue":"8","key":"335_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Medical Care. 2001;39(8):800\u201312.","journal-title":"Medical Care"},{"issue":"11","key":"335_CR32","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/aur.1821","volume":"10","author":"C Vlaskamp","year":"2017","unstructured":"Vlaskamp C, Oranje B, Madsen GF, M\u00f8llegaard Jepsen JR, Durston S, Cantio C, et al. Auditory processing in autism spectrum disorder: Mismatch negativity deficits. Autism Res. 2017;10(11):1857\u201365.","journal-title":"Autism Res"},{"issue":"1","key":"335_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/aur.1337","volume":"7","author":"GF Madsen","year":"2014","unstructured":"Madsen GF, Bilenberg N, Cantio C, Oranje B. Increased prepulse inhibition and sensitization of the startle reflex in autistic children. Autism Res. 2014;7(1):94\u2013103.","journal-title":"Autism Res"},{"key":"335_CR34","doi-asserted-by":"crossref","unstructured":"Madsen GF, Bilenberg N, Jepsen JR, Glenthoj B, Cantio C, Oranje B. Normal P50 Gating in Children with Autism, Yet Attenuated P50 Amplitude in the Asperger Subcategory. 2015 (1939-3806 (Electronic)).","DOI":"10.1002\/aur.1452"},{"issue":"4","key":"335_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00787-005-0443-1","volume":"14","author":"P de Vries","year":"2005","unstructured":"de Vries P, Humphrey A, McCartney D, Prather P, Bolton P, Hunt A, et al. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry. 2005;14(4):183\u201390.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"335_CR36","first-page":"187","volume":"6","author":"L de Sonneville","year":"1999","unstructured":"de Sonneville L. Amsterdam Neuropsychological tasks: a computer-aided assessment program. Cognitive Ergonomics, Clinical Assessment and Computer-assisted Learning: Computers in Psychology. 1999;6:187\u2013203.","journal-title":"Cognitive Ergonomics, Clinical Assessment and Computer-assisted Learning: Computers in Psychology."},{"key":"335_CR37","volume-title":"Statistical power analysis for the behavioral sciences: Routledge","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences: Routledge; 1988."},{"issue":"12","key":"335_CR38","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1111\/j.1651-2227.2010.01933.x","volume":"99","author":"E Lemonnier","year":"2010","unstructured":"Lemonnier E, Ben-Ari Y. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3\u2009months with no side effects. Acta Paediatr. 2010;99(12):1885\u20138.","journal-title":"Acta Paediatr"},{"key":"335_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.124","volume":"2","author":"E Lemonnier","year":"2012","unstructured":"Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry. 2012;2:e202.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"335_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.eplepsyres.2011.01.009","volume":"94","author":"M Miyajima","year":"2011","unstructured":"Miyajima M, Ohta K, Hara K, Iino H, Maehara T, Hara M, et al. Abnormal mismatch negativity for pure-tone sounds in temporal lobe epilepsy. Epilepsy Res. 2011;94(3):149\u201357.","journal-title":"Epilepsy Res"},{"key":"335_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.yebeh.2014.02.017","volume":"33","author":"R Lopes","year":"2014","unstructured":"Lopes R, Sim\u00f5es MR, Ferraz L, Leal AJR. The mismatch negativity (MMN) potential as a tool for the functional mapping of temporal lobe epilepsies. Epilepsy Behav. 2014;33:87\u201393.","journal-title":"Epilepsy Behav"},{"key":"335_CR42","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3389\/fphar.2018.00964","volume":"9","author":"PJ de Vries","year":"2018","unstructured":"de Vries PJ, Franz DN, Curatolo P, Nabbout R, Neary M, Herbst F, et al. Measuring Health-related quality of life in tuberous sclerosis complex\u2014psychometric evaluation of three instruments in individuals with refractory epilepsy. Front Pharmacol. 2018;9:964.","journal-title":"Front Pharmacol"},{"key":"335_CR43","doi-asserted-by":"crossref","unstructured":"Kharod SC, Kang SK, Kadam SD. Off-Label Use of Bumetanide for Brain Disorders: An Overview. Frontiers in neuroscience. 2019;13:310-.","DOI":"10.3389\/fnins.2019.00310"},{"key":"335_CR44","doi-asserted-by":"publisher","unstructured":"Stunnenberg BC, Raaphorst J, Groenewoud HM, Statland JM, Griggs RC, Woertman W, et al. Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. (1538-3598 (Electronic)). https:\/\/doi.org\/10.1001\/jama.2018.18020.","DOI":"10.1001\/jama.2018.18020"}],"container-title":["Molecular Autism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-020-00335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13229-020-00335-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-020-00335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T19:40:39Z","timestamp":1620330039000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularautism.biomedcentral.com\/articles\/10.1186\/s13229-020-00335-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1186\/s13229-020-00335-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737931676.793579850","asserted-by":"object"}]},"ISSN":["2040-2392"],"issn-type":[{"value":"2040-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"23 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The medical ethical committee (METC) of the UMC Utrecht approved the trial protocol and the study is conducted according to the principles of the Declaration of Helsinki, version of Fortaleza, 2013, the International Conference on Harmonisation\u2013Good Clinical Practice (ICH-GCP) and in accordance with the Medical Research Involving Human Subjects Act (WMO). Written informed consent was obtained from all parents and participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}